Critical analysis of clinical evidence generation and biomarker testing infrastructure required to support tumor-agnostic oncology approvals across diverse populations.
Read the full white paper for complete data and regulatory guidance →
SSI Strategy: Tumor-Agnostic Therapies – Challenges in Evidence, Access, and Generalizability
